Principal Financial Group’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-306,298
Closed -$7.38M 2556
2023
Q1
$7.38M Buy
306,298
+67,225
+28% +$844K 0.01% 1396
2022
Q4
$2.53M Buy
239,073
+223,922
+1,478% +$1.81M ﹤0.01% 1723
2022
Q3
$68K Buy
15,151
+153
+1% +$697 ﹤0.01% 2387
2022
Q2
$60K Buy
+14,998
New +$71.1K ﹤0.01% 2449
2021
Q4
Sell
-12,587
Closed -$81K 2676
2021
Q3
$81K Sell
12,587
-2,043
-14% -$13.1K ﹤0.01% 2518
2021
Q2
$123K Sell
14,630
-9,192
-39% -$74.2K ﹤0.01% 2516
2021
Q1
$250K Sell
23,822
-91
-0.4% -$1.28K ﹤0.01% 2327
2020
Q4
$405K Buy
+23,913
New +$358K ﹤0.01% 2169
2020
Q3
Sell
-10,174
Closed -$144K 2370
2020
Q2
$144K Buy
+10,174
New +$128K ﹤0.01% 2220

Other funds holding PRVB

Principal Financial Group's PRVB Position: Q2 2023 in Review

Principal Financial Group sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 306,298 shares — an estimated $7.38M sold.

Principal Financial Group first reported a position in PRVB in Q2 2020 and held it in 9 quarters. The position peaked at $7.38M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

  • Principal Financial Group reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Principal Financial Group sold 306,298 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $7.38M.
  • Principal Financial Group first reported a position in Provention Bio, Inc. Common Stock in Q2 2020 and held it in 9 quarters.
  • Principal Financial Group's Provention Bio, Inc. Common Stock position peaked at $7.38M in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Principal Financial Group's 13F filing for Q2 2023, filed 7 Aug 2023.